CD274 and neoplasm: Mehnert et al. conducted a single-arm, Phase Ib trial (KEYNOTE-28, NCT02054806 [82]) to evaluate the safety and antitumor activity of pembrolizumab in 22 patients with advanced DTC that demonstrated PD-L1 expression in tumor or stromal cells, and had not responded to standard therapy.